drugset / Trial / NCT00136461
A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the effects of the combination of all-trans retinoic acid in combination with one of two schedules of Bryostatin 1 in patients with myelodysplasia and acute myelogenous leukemia.
Timeline
- Start
- 1997-05
- Primary completion
- 2000-08
- Completion
- 2000-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bryostatin 1 | Small molecule | 40 ug/m2 | Intravenous |
| Subject | bryostatin 1 | Small molecule | 60 ug/m2 | Intravenous |
| Background | Tretinoin | Small molecule | 150 mg/m2 | — |